Document Detail


Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries.
MedLine Citation:
PMID:  23086989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Melatonin inhibits nitric oxide (NO)-induced relaxation of coronary arteries. We tested the hypothesis that melatonin increases the phosphorylation of phosphodiesterase 5 (PDE5), which increases the activity of the enzyme and thereby decreases intracellular cGMP accumulation in response to NO and inhibits NO-induced relaxation. Sodium nitroprusside (SNP) and 8-Br-cGMP caused concentration-dependent relaxation of isolated coronary arteries suspended in organ chambers for isometric tension recording. In the presence of melatonin, the concentration-response curve to SNP, but not 8-Br-cGMP, was shifted to the right. The effect of melatonin on SNP-induced relaxation was abolished in the presence of the PDE5 inhibitors zaprinast and sildenafil. Melatonin markedly inhibited the SNP-induced increase in intracellular cGMP in coronary arteries, an effect that was also abolished by zaprinast. Treatment of coronary arteries with melatonin caused a nearly fourfold increase in the phosphorylation of PDE5, which increased the catalytic activity of the enzyme and thereby increased the degradation of cGMP to inactive 5'-GMP. Melatonin-induced PDE5 phosphorylation was markedly attenuated in the presence of the PKG1 inhibitors DT-2 or Rp-8-Br-PET-cGMPS and in those arteries in which PKG1 expression was first downregulated by 24-h incubation with SNP before exposure to melatonin. The selective MT(2) receptor antagonist 4-phenyl-2-propionamidotetralin completely blocked the stimulatory effect of melatonin on PDE5 phosphorylation as well as the inhibitory effect of melatonin on SNP-induced relaxation and intracellular cGMP. Thus, in coronary arteries, melatonin acts via MT(2) receptors and PKG1 to increase PDE5 phosphorylation, resulting in decreased cGMP accumulation in response to NO and impaired NO-induced vasorelaxation.
Authors:
Praveen Shukla; Chengwen Sun; Stephen T O'Rourke
Related Documents :
11265089 - Internal to external carotid artery transposition to repair recurrent stenosis after ca...
12578419 - Revascularization of the internal carotid artery for isolated, stenotic, and symptomati...
8905069 - Two unusual variants of internal carotid artery aneurysms due to fibromuscular dysplasia.
9404209 - The agreement between colour doppler systems in measuring internal carotid artery peak ...
16224089 - Variation in the carotid bifurcation geometry of young versus older adults: implication...
19682709 - Ischemic stroke patterns and hemodynamic features in patients with small vertebrobasila...
23388239 - Percutaneous closure of iatrogenic ventricular septal defect following surgical aortic ...
1828649 - Stenoses of vascular anastomoses after hepatic transplantation: treatment with balloon ...
1581079 - Surgical repair of a postendocarditis abscess cavity in the heart guided by intraoperat...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-10-19
Journal Detail:
Title:  American journal of physiology. Heart and circulatory physiology     Volume:  303     ISSN:  1522-1539     ISO Abbreviation:  Am. J. Physiol. Heart Circ. Physiol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-17     Completed Date:  2013-04-09     Revised Date:  2013-12-18    
Medline Journal Info:
Nlm Unique ID:  100901228     Medline TA:  Am J Physiol Heart Circ Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  H1418-25     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Coronary Vessels / metabolism*
Cyclic GMP / analogs & derivatives,  metabolism,  pharmacology
Cyclic GMP-Dependent Protein Kinases / metabolism
Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism*
Melatonin / pharmacology*
Models, Animal
Nitric Oxide / antagonists & inhibitors*,  metabolism*
Nitroprusside / pharmacology
Phosphorylation / drug effects
Receptor, Melatonin, MT2 / metabolism
Signal Transduction / drug effects*,  physiology
Swine
Vasodilation / drug effects
Grant Support
ID/Acronym/Agency:
HL-77204/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Receptor, Melatonin, MT2; 169D1260KM/Nitroprusside; 31356-94-2/8-bromocyclic GMP; 31C4KY9ESH/Nitric Oxide; EC 2.7.11.12/Cyclic GMP-Dependent Protein Kinases; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5; H2D2X058MU/Cyclic GMP; JL5DK93RCL/Melatonin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  H2O2-induced endothelial NO production contributes to vascular cell apoptosis and increased permeabi...
Next Document:  Left Atrial and Ventricular Function during Dobutamine and Glycopyrrolate Stress in Healthy Young an...